BioSpace News Archive

Researchers with Sun Genomics and Arizona State University have discovered that probiotic supplementation may improve symptoms in people with autism spectrum disorder.

SI-BONE, Inc. announced the first cases completed with the smaller, 9.5 mm diameter, iFuse Bedrock Granite® Implant.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States.

Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron.

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced that company management will participate in a fireside chat at two upcoming investor conferences.

RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™).

Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) will publish the company’s interim report for the first quarter 2024 on Tuesday, May 21, 2024, at 07:00 a.m. CEST.

Boehringer Ingelheim announced that SENVELGO™, a revolutionary new treatment for cats with diabetes, has been approved by Health Canada, marking a significant step in the treatment of feline diabetes in Canada.

TerSera Canada Inc. today announced that Health Canada has approved a supplemental New Drug Submission for ZOLADEX LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women.

Edgewise Therapeutics, Inc. announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors.